Novel immunotherapeutics against LGR5 to target multiple cancer types

Novel immunotherapeutics against LGR5 to target multiple cancer types

Abstract We have developed and validated a highly specific, versatile antibody to the extracellular domain of human LGR5 (α-LGR5). α-LGR5 detects LGR5 overexpression in >90% of colorectal cancer (CRC), hepatocellular carcinoma (HCC) and pre-B-ALL tumour cells and was used to generate an Antibody-...

Full description

Bibliographic Details
Main Authors: Hung-Chang Chen, Nico Mueller, Katherine Stott, Chrysa Kapeni, Eilidh Rivers, Carolin M Sauer, Flavio Beke, Stephen J Walsh, Nicola Ashman, Louise O’Brien, Amir Rafati Fard, Arman Ghodsinia, Changtai Li, Fadwa Joud, Olivier Giger, Inti Zlobec, Ioana Olan, Sarah J Aitken, Matthew Hoare, Richard Mair, Eva Serrao, James D Brenton, Alicia Garcia-Gimenez, Simon E Richardson, Brian Huntly, David R Spring, Mikkel-Ole Skjoedt, Karsten Skjødt, Marc de la Roche, Maike de la Roche
Format: Article
Language:English
Published: Springer Nature 2024-08-01
Series:EMBO Molecular Medicine
Subjects:
LGR5
Cancer Immunotherapeutics
ADC
BiTE
CAR
Online Access:https://doi.org/10.1038/s44321-024-00121-2

Internet

https://doi.org/10.1038/s44321-024-00121-2

Similar Items